The U.S. Food and Drug Administration approved the Autus Size-Adjustable Valve on October 1, 2026, making it the first heart valve designed to be expanded after implantation as a child grows. The surgically implanted pulmonary valve is intended for pediatric patients with congenital pulmonary valve disease and can later be widened with a balloon catheter rather than replaced through another open-heart operation.
The valve is designed to address a problem unique to growing children
The pulmonary valve sits between the right ventricle and the pulmonary artery, controlling blood flow from the heart to the lungs. Congenital abnormalities such as pulmonary stenosis, in which the valve is narrowed, and pulmonary atresia, in which the valve does not form normally, can restrict that flow and require surgical repair early in life.
Even after repair, some children later develop substantial pulmonary regurgitation, meaning blood leaks backward through the valve. Over time, that can enlarge or weaken the right ventricle and create a need for pulmonary valve replacement.
That is where pediatric valve replacement becomes difficult. A conventional prosthetic valve does not grow with the child. A valve that is appropriately sized for a young child can become too small as the heart and body grow, creating the possibility of another operation to replace it.
The problem is fundamentally different from acquired cardiovascular disease such as silent atherosclerosis, where treatment is aimed at slowing plaque progression rather than accommodating growth of the heart itself.
Autus can be expanded after implantation
The Autus valve was built to change size. According to the FDA, it can be implanted at an internal diameter of about 13 millimeters, a size suitable for a toddler or preschool-aged child, and later expanded to as much as 22 millimeters.
The expansion is performed with a balloon catheter. A catheter carrying a small inflatable balloon is advanced to the valve, where the balloon is inflated to widen the valve frame. That means a child who begins to outgrow the valve may be able to have it enlarged through a transcatheter procedure rather than undergo another open-heart surgery solely because the original valve has become too small.
The concept also differs from treatments for disorders of the pulmonary circulation such as pulmonary arterial hypertension. Autus is a structural device that replaces the pulmonary valve itself, not a drug that changes pressure or signaling within pulmonary blood vessels.
The valve uses synthetic leaflets instead of animal tissue
Autus is also notable for the material used in its leaflets, the flaps that open and close with each heartbeat. The FDA described it as the first valve approved in the United States to use polymeric leaflet material rather than animal-derived tissue.
Traditional tissue valves commonly use biologic material derived from animals. In children, those valves can deteriorate more quickly than they do in adults, partly because calcification and degeneration can occur over time. The Autus valve instead uses synthetic polymeric leaflets mounted on an expandable metal frame.
Earlier first-in-human data provide some of the evidence behind that design. In an 11-patient early feasibility study published in The Journal of Thoracic and Cardiovascular Surgery, children were followed for one year after implantation. Ten had no pulmonary regurgitation at one year and one had trivial regurgitation. No deaths, valve thrombosis, endocarditis or device-related adverse events were reported in that small study.
Those results were encouraging, but the sample was too small to establish long-term durability. The larger pivotal program was needed before FDA approval.
The pivotal study enrolled 62 pediatric patients
The FDA based its approval on a clinical study that enrolled 62 pediatric patients at 12 U.S. sites. The pivotal study was prospective, single-arm and multicenter, meaning every participant received the device and there was no randomized control group.
At six months, the first 60 patients had what the FDA described as acceptable hemodynamic performance, with blood flow through the right side of the heart remaining within acceptable limits and no more than mild pulmonary regurgitation.
All 62 implantation procedures were successful. The FDA reported no deaths, strokes, blood clots requiring additional treatment or other clot-related complications during the reported follow-up.
There were, however, device findings that will require continued observation. Three patients experienced fractures in the valve frame, and two had reduced movement of one leaflet. The FDA said none of those events caused symptoms at the time they were reported.
Only two patients had required post-implant expansion at the time of approval
The feature that makes Autus unusual is also the feature for which the clinical experience is currently most limited.
Valve performance began to deteriorate in two children as they started to outgrow the implanted valve. In both cases, clinicians successfully enlarged the valve with a balloon catheter without another open surgical procedure.
That is an important proof of concept, but two cases are not enough to determine how reliably repeated expansion will work across different ages, body sizes and years of growth. The FDA explicitly noted that longer-term studies are underway to determine whether expansion can preserve valve function and actually reduce the number of future surgeries.
Patients in the continued-access program are scheduled for annual follow-up for as long as 10 years, reflecting how long it may take to answer the durability question.
The approval does not mean every child can avoid future valve surgery
The most appealing implication of Autus is the possibility of fewer open-heart operations over childhood, but that outcome has not yet been demonstrated over the full period of growth from early childhood into adulthood.
The FDA approval shows that the agency found reasonable assurance of safety and effectiveness based on the available nonclinical and clinical evidence. It does not establish that one Autus valve will last for an entire childhood, that every implanted valve can be expanded to the maximum diameter, or that repeat surgery will never be required.
Long-term questions include durability of the polymeric leaflets, the significance of frame fractures, how the valve behaves after one or more balloon expansions, and whether structural changes emerge years after implantation.
That distinction is similar to other pediatric medical advances, where approval answers whether a product can be used for a defined indication but continued follow-up is needed to understand performance across many years. Bites of Bio has seen the same issue in pediatric prevention, where age, growth and duration of protection matter for products such as RSV prevention for infants.
The approval is a first for pediatric structural heart care
Autus received FDA Breakthrough Device designation before approval and was reviewed through the premarket approval pathway, the FDA’s most stringent medical-device review route for high-risk devices.
It is also the first pediatric approval to emerge from the FDA’s Total Product Life Cycle Advisory Program, which is intended to bring regulators and device developers into earlier and more continuous contact during development.
For pediatric heart surgery, however, the core advance is simpler: the device was designed around the fact that the patient will grow. If long-term follow-up confirms that the valve can be enlarged safely and remain functional over time, it could change how congenital heart teams plan pulmonary valve replacement for children who would otherwise face repeated operations as their bodies get larger.
References
- U.S. Food and Drug Administration. FDA Approves First Heart Valve Designed to Grow with Children. October 1, 2026. FDA press release.
- ClinicalTrials.gov. Autus Valve Pivotal Study. NCT05006404. Clinical trial record.
- Galantowicz ME, Stiver CA, Barry OM, et al. Novel size-adjustable pulmonary valve US early feasibility study: One-year outcomes. J Thorac Cardiovasc Surg. 2025;170(6):1739-1746. DOI: 10.1016/j.jtcvs.2025.07.035.
- ClinicalTrials.gov. Autus Valve Continued Access Study. NCT07466745. Clinical trial record.